Chai Discovery · client: Pfizer
Pfizer announced a licensing agreement with Chai Discovery that gives it early access to the new Chai-3 AI platform, which could improve its ability to identify and design new drug…
Company lists
Life sciences technology, genomics, oncology, platforms and tools, startups and more: the companies building life sciences in San Francisco, California, with their founders, funding, team size and business models.
Funding, M&A, contract wins and launches involving 1,084 life sciences companies in San Francisco, last 24 months: 104 funding rounds · 92 M&A deals · 35 Contracts · 2 launches. Newest first; companies and investors link to their Fliar profiles. Latest event in our news feed: Jun 2026.
Pfizer announced a licensing agreement with Chai Discovery that gives it early access to the new Chai-3 AI platform, which could improve its ability to identify and design new drug…
Triomics has raised USD $22 million in Series B funding in a round led by Battery Ventures.
announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE: RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million.
Innovaccer Inc., a leading healthcare AI company, today announced the asset acquisition of CaduceusHealth, a nationally recognized revenue cycle management services provider.
Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was 'transformational,' highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million…
We are pleased to submit this further improved, non-binding proposal to acquire 100% of the equity of the Company for $2.40 per share in cash, which represents an immediate 42% premium…
Robo.ai Inc. (NASDAQ:AIIO) said Thursday it agreed to acquire Neurovia AI Limited, a data processing and compression technology company, in a $100 million all-stock deal aimed at…
The Leverkusen take over the US biotech company Perfuse Therapeutics, which specializes in ophthalmology. The deal has a volume of up to 2.45 billion dollars
Belgian biopharma UCB is set to take over California-based Neurona Therapeutics for up to $1.15 billion.
Transaction represents total equity value of approximately $2.5 billion. Servier ... today announced the successful completion of the tender offer to acquire all of the issued and…
The pharmaceutical group acquires the American Neurona Therapeutics, thus strengthening its portfolio with promising research on a new treatment against epilepsy. The acquisition amount…
Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic…
Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic…
Spyre Therapeutics, Inc. (“Spyre” or the “Company”) announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a price to…
Terremoto Biosciences Raises $108M Series C for selective AKT1 therapies in oncology and rare disease
Aurina aims to acquire all outstanding shares of Kezar Life Sciences.
Allogene Therapeutics, Inc. (Nasdaq: ALLO ) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million…
The Radoff-JEC Group, which owns approximately 7.6% of Seer's outstanding shares, proposed to acquire 100% of the company for $2.25 per share in cash, representing a 33% premium to the…
Emerging biotechnology company aims to unlock targeting of disease-specific epigenetic protein interfaces to develop next‑generation therapies for pediatric cancers SAN…
Gilead recently agreed to buy autoimmune disease–focused Ouro Medicines for $1.7 million up front
On April 1, 2026, Kezar Life Sciences, Inc. announced that it has entered into an Agreement and Plan of Merger with Aurinia Pharma U.S., Inc. ("Aurinia" or "Parent"), a Delaware…
Aurinia Pharmaceuticals announced that it has entered into a definitive merger agreement to acquire Kezar Life Sciences, Inc. for $6.955 in cash per share, along with a contingent value…
Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, announced the closing of a $37…
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs,…
$2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrants BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) --…
Biomemory has acquired selected assets from Catalog Technologies, a pioneer in DNA-based data storage and computing systems.
GlaxoSmithKline (GSK) in January committed $2.2 billion to acquire Rapt Therapeutics
Last September, Servier paid Ideaya Biosciences $230 million up front for rights outside of the U.S. to darovasertib, which is in late‑stage development for a rare type of eye cancer.
Tamarind Bio – $13.6M
Astellas Pharma Inc. and Vir Biotechnology Inc. have signed a global co-development pact to advance VIR-5500, Vir’s PRO-XTEN dual-masked CD3 T-cell engager targeting prostate-specific…
Few life sciences companies in San Francisco, California publish revenue, so this list compares what is on record instead: recorded equity funding, team size, revenue model, age and stage. The 50 companies below lead on recorded funding and team size among 774 active companies.

AI-enabled platform for drug discovery and development
Life sciences techEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of machine learning platform for drug discovery and development
Artificial intelligenceUS$643.21m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: AI-driven biomedical data analysis and disease modeling for drug discovery and diagnostics
CPC G06V20/69, G06T7/0012, G16B40/20Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of immune cell therapies for cancer treatment
OncologyUS$631.16m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Manufacturer of a medical device for cell-based therapy
Life sciences platforms and toolsUS$612.00m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in transport & manufacturing processes
CPC B01L3/502715, C12M41/48, C12M35/02Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of healthcare data platforms and artificial intelligence agent software
Big data analyticsUS$557.35m across 8 disclosed equity rounds
Darker bars = larger roundsFocus: Integrating and analyzing de‑identified healthcare data across clouds for clinical decision support
CPC G16H10/60, G06F21/6254, G06F8/36Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of chimeric antigen receptor cell therapy to treat cancer
ImmunotherapyUS$531.77m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Engineering allogeneic CAR‑T cells with immune‑evasion, switch receptors, and dosing technologies
CPC C12N5/0636, C07K14/715, A61K35/17Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapeutics for the treatment of auto-immune disease
ImmunologyUS$529.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: TYK2 kinase inhibitor compounds and formulations for inflammatory disease treatment.
CPC C07D401/14, C07D401/12, C07D498/22Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of CAR- T therapy for cancer treatment
ImmunotherapyFocus: Engineering and manufacturing of enhanced CAR‑T cells and cytokine gene therapies
CPC C12N5/0636, C07K14/7051, C07K14/71Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of antibodies to modulate the activity of immunosuppressive cells in the tumor microenvironment
ImmunotherapyUS$475.00m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of a genomic database for clinical research
Healthcare booking platformsUS$435.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Genomic sequencing data management and cardiac genomics diagnostics analytics
CPC C12N15/8273, B21C37/121, G16B20/20Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of biologics to treat hepatitis B infection
Infectious diseasesUS$415.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Antiviral nucleoside analogs/capsid inhibitors and neurosteroid-based CNS therapeutics
CPC A61K31/7076, C07J17/00, A61K31/568Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of a cloud-based bioinformatics platform for biotech research
GenomicsUS$411.90m across 8 disclosed equity rounds
Darker bars = larger roundsFocus: Cloud-based bioprocess workflow and molecular design data management platform.
CPC G05B19/41865, G16C20/40, G06F21/6227Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Company provides healthcare analytics and value-based payments platform services
Healthcare itUS$410.97m across 8 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of therapies for metabolic health in chronic disease patients
Healthcare itUS$401.78m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: Cable‑suspended overland material handling and transport conveyor systems
CPC B65G21/04Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of cell-free cancer liquid biopsy test
GenomicsUS$388.62m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: cfDNA methylation quantification and sequencing assay quality control for diagnostics
CPC C12Q1/6876, G16B40/00, C12Q1/6883Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of biologics for the treatment of cardio-metabolic and liver disease
GastroenterologyUS$358.87m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: Therapeutic antibodies and peptide drugs targeting ILT, glucagon, and GFRAL receptors
CPC A61K38/1825, C07K14/495, C07K16/28Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of small-molecule therapeutics for cancer treatment
OncologyUS$358.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapies to treat neurodegenerative diseases
NeurologyUS$347.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Neurodegenerative antibody therapies and enzyme‑fusion biologics for lysosomal disease treatment
CPC C07D403/12, C07K16/2803, C07K16/2881Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of T-cell-based therapies for autoimmune and degenerative diseases
ImmunologyUS$335.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Engineered immune cell therapies using chimeric antigen receptors and cytokine receptor designs
CPC C07K16/36, A61K40/22, C12N5/0637Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of a semiconductor-based DNA synthesis platform
Life sciences platforms and toolsUS$320.76m across 9 disclosed equity rounds
Darker bars = larger roundsFocus: Synthetic DNA manufacturing, custom nucleic acid libraries, and related hybridization/enzymatic technologies.
CPC B01J19/0046, C07K16/2869, C12N15/1093Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

AI-based drug discovery model for researchers
Life sciences techUS$310.00m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: LRRK2 kinase inhibitor therapeutics and biomarkers for Parkinson's disease treatment
CPC C12Q1/6883, C07D471/04, G16B30/00Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of an AI platform for discovering and designing novel drugs
Generative aiUS$304.02m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Online platform for clinical trail data analytics and management software for researchers
Life sciences techUS$287.80m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapies for immunological diseases and cancer
ImmunologyUS$267.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

All-in-one blood glucose monitoring system
DiabetesUS$258.45m across 14 disclosed equity rounds
Darker bars = larger roundsFocus: Point‑of‑care fluid sampling and analyte measurement devices for medical diagnostics
CPC A61B5/157, A61B5/150984, A61B5/14532Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of an AI-powered platform for care coordination and disease detection
Healthcare itUS$251.99m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: AI-powered clinical triage for stroke, aneurysm, and cardiac signal analysis
CPC G06T7/0012, G16H30/40, G06Q10/06311Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of an AI-based clinical decision supporting tool for cancer detection and drug development
OncologyUS$250.90m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of brain-computer interfaces to maximize human ability, agency, experience
NeurologyFocus: Real-time multi-user AR streaming and collaborative 3D object interaction
CPC G02B27/0176, G06F3/0346, H04L65/60Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of regenerative and gene therapeutics for heart failure
Gene therapyUS$248.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Engineered AAV gene‑therapy vectors and CRISPR guides for cardiac PLN mutation treatment
CPC C12N15/86, A61K48/0058, C07K14/005Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension
Life sciences techUS$247.25m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of viral gene therapy
GenomicsUS$239.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of a bioinformatics platform for drug development and chemoproteomics
Life sciences techUS$235.50m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: KRAS G12C mutant inhibition using pyrido‑pyrimidine compounds for cancer therapy
CPC C07D519/00, A61P35/00, C07D487/04Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of artificial intelligence models for de novo molecular design
Generative aiUS$230.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of protein degradation drugs for the treatment of cancer and auto-immune disease
ImmunologyUS$226.66m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapies to treat hepatologic diseases and viral infections
Metabolic diseasesUS$225.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: RNA interference therapeutics and PD‑L1 immuno‑oncology using heterocyclic siRNA delivery compounds
CPC C07D403/12, C07D487/04, C12N15/1131Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of stem cell secreted factors for the treatment of myocardial infarction and stroke
Cardiac and vascular disordersUS$220.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapeutics for immunology and cancer
ImmunologyUS$219.00m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of artificial intelligence platform for small molecule drug discovery
Generative aiUS$218.64m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: AI-driven discovery of small‑molecule inhibitors and virtual chemical library screening
CPC G06N3/086, G16B15/00, G06N3/08Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of immunotherapies for the treatment of cancer and autoimmune diseases
OncologyUS$218.12m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C07K16/2815, A61K47/6813, C07K14/5428Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapeutics for the treatment of infectious diseases
Infectious diseasesUS$216.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Broadly neutralizing antiviral antibodies and combination therapies for hepatitis B and respiratory viruses
CPC C07K16/108, C07K16/104, C07K16/10Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of antibody therapies for multiple diseases
ImmunotherapyUS$215.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders
NeurologyUS$214.78m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Therapeutic antibodies targeting neurodegeneration and immune modulation proteins.
CPC C07K16/2803, C07K16/28, C07K16/286Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology.
OncologyUS$213.52m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: Therapeutics targeting HIF prolyl hydroxylase inhibition and immuno‑modulatory antibodies (galectin‑9, CCR8).
CPC C07D217/26, A61K31/472, C07K16/22Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of macrocycle therapeutics to treat cancer and other serious illnesses
OncologyUS$210.25m across 5 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Microfluidic-based biomarkers for the early detection of sepsis
Infectious diseasesUS$206.78m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: Point-of-care diagnostic platforms for immune activity and sepsis monitoring
CPC B01L3/502761, G01N15/0227, B01L3/502776Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Develope of synthetic neo-antigen targeting TILs through T cell isolation platform
ImmunotherapyUS$200.50m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of small molecule therapies for neurological, cardiometabolic, and ophthalmic diseases
NeurologyEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of drugs for the treatment of Amyloid diseases
ImmunologyUS$197.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Engineered Fc‑fusion and antibody‑peptide biologics for amyloid disease therapy
CPC C07K16/18, A61K51/1096, A61P25/28Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases
ImmunologyUS$196.58m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Provider of replacement therapies for rare genetic diseases
Rare diseasesUS$195.00m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in health & consumer products
CPC A61K9/1271, A61K31/7032, C07H11/04Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
No matching company in this list.
This page shows the top 50. Radar has the complete, filterable list with contacts and live company signals.
Open life sciences in San Francisco on RadarFind top life sciences companies in San Francisco for science technology, genomics, oncology, and research platforms. Explore life sciences companies in San Francisco by the care and research areas they serve.
Companies building digital tools and technology for life sciences work.

Developer of healthcare data platforms and artificial intelligence agent software
Big data analytics
Company provides healthcare analytics and value-based payments platform services
Healthcare it
Provider of therapies for metabolic health in chronic disease patients
Healthcare it
Online platform for clinical trail data analytics and management software for researchers
Life sciences tech
Developer of an AI-powered platform for care coordination and disease detection
Healthcare itCompanies working with genetic data, testing, and clinical diagnostics.

Provider of a genomic database for clinical research
Healthcare booking platforms
Provider of diagnostic solutions for systemic infections
Genomics
Provider of home-based genetic test for individuals
Genomics
Developer of a platform for detection of cancer
Genomics
Provider of non-invasive diagnostic tests for pregnant women
Women healthCompanies developing cancer diagnostics, therapies, and research.

Developer of immune cell therapies for cancer treatment
Oncology
Developer of chimeric antigen receptor cell therapy to treat cancer
Immunotherapy
Developer of CAR- T therapy for cancer treatment
Immunotherapy
Developer of antibodies to modulate the activity of immunosuppressive cells in the tumor microenvironment
Immunotherapy
Provider of cell-free cancer liquid biopsy test
GenomicsProviders of research platforms, laboratory tools, and scientific services.

Manufacturer of flow cytometry systems for research applications
Life sciences platforms and tools
Provider of biomanufacturing hardware and software tools for research purposes
Life sciences platforms and tools
Developer of cell culture analysis device for cancer research
Genomics
Developer of cell processing platforms for research and industries
Life sciences platforms and tools
Provider of technologies and solutions genomic research and precision medicine
GenomicsRecently founded life sciences companies in San Francisco.

AI-enabled platform for drug discovery and development
Life sciences tech
Developer of small-molecule therapeutics for cancer treatment
Oncology
Developer of brain-computer interfaces to maximize human ability, agency, experience
Neurology
Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension
Life sciences tech
Developer of artificial intelligence models for de novo molecular design
Generative aiLife sciences companies in San Francisco with hiring activity.

AI-enabled platform for drug discovery and development
Life sciences tech
Manufacturer of a medical device for cell-based therapy
Life sciences platforms and tools
Developer of healthcare data platforms and artificial intelligence agent software
Big data analytics
Developer of chimeric antigen receptor cell therapy to treat cancer
Immunotherapy
Developer of therapeutics for the treatment of auto-immune disease
ImmunologyPublicly listed life sciences companies in San Francisco.

Developer of chimeric antigen receptor cell therapy to treat cancer
Immunotherapy
Developer of therapeutics for the treatment of auto-immune disease
Immunology
Developer of CAR- T therapy for cancer treatment
Immunotherapy
Developer of biologics to treat hepatitis B infection
Infectious diseases
Provider of cell-free cancer liquid biopsy test
GenomicsThe most-installed Android apps published by life sciences companies headquartered in San Francisco — 6.9M installs between them. 28 companies on this page publish at least one app; each company (legal entity) appears once, with its most-installed app.
The figures on this page come from Fliar’s company, funding, hiring and news data. Use it through the Investor Intelligence API and company data exports, or explore every company, founder and investor in Radar.
22,455 recorded equity rounds have gone to 27,407 life sciences companies in the United States — how much, at which stage, into which sub-sectors, from whom, and how San Francisco compares. Debt, IPO and grant rounds are excluded.
US$13.54bn
US$37.38bn
5,603 rounds in the United States
last 24 months
Bars show US$ raised; the number under each year is equity rounds. 2026 is year to date. The peak year was 2021, with US$45.29bn across 1383 rounds.
Equity rounds over the last five years, 1,084 life sciences companies in San Francisco among 27,407 in the United States.
Each deal appears in the events strip at the top of the page.
Go deeper in the life sciences landscape reports:
Life Sciences Industry Landscape of San Francisco Life Sciences Industry Landscape of the United States Accounting and Tax Software Industry Landscape of San FranciscoThe financials above are one chapter. The full life sciences landscape of San Francisco maps the whole industry — every segment, the capital behind it, the talent market and where the next opportunities are.
401 life sciences companies in San Francisco have recorded equity funding, US$28.79bn in total. Totals and round dates describe the historical record; they are not current valuations.
Largest recorded equity totals, with the latest recorded round.
Life sciences techAI-enabled platform for drug discovery and development
Artificial intelligenceDeveloper of machine learning platform for drug discovery and development
OncologyDeveloper of immune cell therapies for cancer treatment
Life sciences platforms and toolsManufacturer of a medical device for cell-based therapy
Big data analyticsDeveloper of healthcare data platforms and artificial intelligence agent software
ImmunotherapyDeveloper of chimeric antigen receptor cell therapy to treat cancer
Founders
Details not available
ImmunologyDeveloper of therapeutics for the treatment of auto-immune disease
ImmunotherapyDeveloper of CAR- T therapy for cancer treatment
ImmunotherapyDeveloper of antibodies to modulate the activity of immunosuppressive cells in the tumor microenvironment
Founders
Details not available
Healthcare booking platformsProvider of a genomic database for clinical research
Infectious diseasesDeveloper of biologics to treat hepatitis B infection
GenomicsProvider of a cloud-based bioinformatics platform for biotech research
Healthcare itCompany provides healthcare analytics and value-based payments platform services
Healthcare itProvider of therapies for metabolic health in chronic disease patients
GenomicsProvider of cell-free cancer liquid biopsy test
GastroenterologyDeveloper of biologics for the treatment of cardio-metabolic and liver disease
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$643.21m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: AI-driven biomedical data analysis and disease modeling for drug discovery and diagnostics
CPC G06V20/69, G06T7/0012, G16B40/20Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$631.16m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$612.00m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in transport & manufacturing processes
CPC B01L3/502715, C12M41/48, C12M35/02Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$557.35m across 8 disclosed equity rounds
Darker bars = larger roundsFocus: Integrating and analyzing de‑identified healthcare data across clouds for clinical decision support
CPC G16H10/60, G06F21/6254, G06F8/36Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$531.77m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Engineering allogeneic CAR‑T cells with immune‑evasion, switch receptors, and dosing technologies
CPC C12N5/0636, C07K14/715, A61K35/17Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$529.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: TYK2 kinase inhibitor compounds and formulations for inflammatory disease treatment.
CPC C07D401/14, C07D401/12, C07D498/22Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Engineering and manufacturing of enhanced CAR‑T cells and cytokine gene therapies
CPC C12N5/0636, C07K14/7051, C07K14/71Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$475.00m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$435.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Genomic sequencing data management and cardiac genomics diagnostics analytics
CPC C12N15/8273, B21C37/121, G16B20/20Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$415.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Antiviral nucleoside analogs/capsid inhibitors and neurosteroid-based CNS therapeutics
CPC A61K31/7076, C07J17/00, A61K31/568Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$411.90m across 8 disclosed equity rounds
Darker bars = larger roundsFocus: Cloud-based bioprocess workflow and molecular design data management platform.
CPC G05B19/41865, G16C20/40, G06F21/6227Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$410.97m across 8 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$401.78m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: Cable‑suspended overland material handling and transport conveyor systems
CPC B65G21/04Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$388.62m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: cfDNA methylation quantification and sequencing assay quality control for diagnostics
CPC C12Q1/6876, G16B40/00, C12Q1/6883Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$358.87m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: Therapeutic antibodies and peptide drugs targeting ILT, glucagon, and GFRAL receptors
CPC A61K38/1825, C07K14/495, C07K16/28Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Meet the people behind life sciences companies in San Francisco. 585 of 774 companies list founders or leaders; where a public LinkedIn profile matches exactly, the expanded profile shows the photo, headline, location and education.
Companies whose recorded headcount rose the most between the two most recent team-size snapshots. A larger team is a signal of momentum, not of profitability.
Nuclear energyProvider of radiation detection, measurement, analysis and monitoring products and services
Life sciences techOnline platform providing digital tools and services for extracting and analyzing 3D tissue data from histopathology samples
Metabolic diseasesDeveloper of small molecule therapies for the treatment of kidney diseases
OncologyDeveloper of small molecule-based therapeutic solutions for treating cancer
Food techOnline subscription recipe box with pre measured ingredients
Nutraceuticals techDeveloper of clinically-tested Urolithin A supplements and skincare products
Life sciences platforms and toolsAI-driven platform for regulated drug testing and quality analysis
Life sciences techWeb-based software solutions that enable life sciences organizations to improve clinical trial performance
Many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded and lost from the cell.
Founders
Details not available
Life sciences techDeveloper of a platform for next-generation protein sequencing
Life sciences platforms and toolsAssays, cell lines and reagents for drug discovery research
Founders
Details not available
NeurologyDeveloper of therapeutics for neurological disorders
Focus: Radiation detection and dosimetry instrumentation for monitoring ionizing radiation levels.
CPC G01T1/026, G01T1/185, G01T1/17Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$20.69m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$1.55m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Chemically inducible dimerization platforms for bispecific T‑cell engager and Fc fusion therapeutics
CPC C07K16/2803, C07K14/7158, A61P35/00Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$123.63m across 7 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$17.81m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$39.20m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Innovative chemistries for single‑molecule protein/peptide sequencing using guanidinylation and polymerizable coupling.
CPC G01N33/6818, C12Q1/6869, G01N33/6824Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$71.87m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Life sciences companies in San Francisco with at least one woman on the founding team. Expand a profile to meet the founders; teams can include both women and men.
GenomicsProvider of home-based genetic test for individuals
Life sciences platforms and toolsDeveloper of a semiconductor-based DNA synthesis platform
GenomicsDeveloper of genomics-based diagnostics for cancer
Food techProvider of prepared meals, snacks, and juices with delivery options
Artificial intelligenceDeveloper of machine learning platform for drug discovery and development
GenomicsDeveloper of viral gene therapy
Nutraceuticals techProvider of AI based platform to discover plant bio actives for human health
Life sciences platforms and toolsProvider of animal microbiome based diagnostics services for pet care
OncologyDeveloper of small-molecule therapeutics for the treatment of cancer
OncologyDeveloper of immunotherapies for the treatment of cancer and autoimmune diseases
Infectious diseasesDeveloping gastrointestinal products for human prescription use and animals
Life sciences techDeveloper of artificial intelligence powered platform for drug discovery and development
US$189.56m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in computing, sensing & instrumentation
CPC G16B20/20, C12Q1/6827, C12Q1/6869Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$320.76m across 9 disclosed equity rounds
Darker bars = larger roundsFocus: Synthetic DNA manufacturing, custom nucleic acid libraries, and related hybridization/enzymatic technologies.
CPC B01J19/0046, C07K16/2869, C12N15/1093Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$67.90m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C12Q1/6886, C12Q1/6883, G16B25/10Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$16.95m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$643.21m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: AI-driven biomedical data analysis and disease modeling for drug discovery and diagnostics
CPC G06V20/69, G06T7/0012, G16B40/20Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$239.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$120.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Nutraceutical compounds targeting metabolic, stress, and sleep pathways via GPCR modulation
CPC A61K31/165, A23L33/105, A61K31/352Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$25.88m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$108.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$218.12m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C07K16/2815, A61K47/6813, C07K14/5428Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$11.61m across 7 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$134.12m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Life sciences companies in San Francisco founded in the last four years, newest first.
Hospital equipmentDeveloper of tankless dive gear and oxygen generation systems
Rare diseasesDeveloper of AI-enabled therapeutics for rare diseases with high unmet need
Developer of therapeutics focused on addressing unmet needs in renal disease
Founders
Details not available
Life sciences techProvider of AI-powered GxP validation and compliance solutions for life sciences
Founders
Details not available
Life sciences platforms and toolsDeveloper of RNA foundation models for precision medicine research applications
Life sciences platforms and toolsProvider of AI-native protein characterization platform for biopharma
NeurologyDeveloper of brain-computer interfaces to maximize human ability, agency, experience
Life sciences techDeveloper of therapies targeting autoimmune diseases by leveraging parasite biology
Provider of molecular diagnostic testing services for identifying cancer vulnerabilities
Life sciences techDeveloper of an AI regulatory platform for life sciences submissions
Life sciences platforms and toolsDeveloper of AI to predict missing patient data modalities
Clinical labs itOnline platform providing educational and research services in healthcare and medical imaging analytic
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$5.30m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Real-time multi-user AR streaming and collaborative 3D object interaction
CPC G02B27/0176, G06F3/0346, H04L65/60Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Companies with the most distinct news events in the last 24 months across the business press Fliar tracks.
OncologyDeveloper of small molecule drugs for the treatment of cancer
Life sciences platforms and toolsDeveloper of therapeutics to treat multiple diseases
OncologyDeveloper of drugs for hematologic disorders, cancer, and rare immune disease
Life sciences platforms and toolsDeveloper of a semiconductor-based DNA synthesis platform
ImmunotherapyDeveloping targeted, immune-mediated oral cancer therapies for broad patient benefit
Founders
Details not available
Wearable technologyProvider of cloud-based cardiac rhythm monitoring devices
OncologyDeveloper of targeted antibody and T-cell therapeutics for treating multiple diseases
Cardiac and vascular disordersDeveloper of medical remote monitoring solutions that help prevent and manage chronic diseases
GenomicsProvider of cell-free cancer liquid biopsy test
OncologyDeveloper of small-molecule drugs for the treatment of cancers
OrthopedicsDeveloper of muscle activators as potential treatments for debilitating diseases
GenomicsDeveloper of genomics-based diagnostics for cancer
Focus: Small-molecule kinase inhibitors targeting cancer signaling pathways
CPC A61K31/47, C07D215/233, C07D471/04Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Patents concentrated in computing, sensing & instrumentation
CPC G01N33/5008, A61K9/2009, C11B13/00Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$320.76m across 9 disclosed equity rounds
Darker bars = larger roundsFocus: Synthetic DNA manufacturing, custom nucleic acid libraries, and related hybridization/enzymatic technologies.
CPC B01J19/0046, C07K16/2869, C12N15/1093Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$88.19m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$98.88m across 9 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$52.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Wearable cardiac monitoring devices integrating touch-sensitive electrode displays
CPC G06F3/041661, A61B5/282Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$388.62m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: cfDNA methylation quantification and sequencing assay quality control for diagnostics
CPC C12Q1/6876, G16B40/00, C12Q1/6883Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$173.40m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Small-molecule oncology drugs targeting epigenetic regulators, EGFR mutants, CD73, and AKT pathways.
CPC C07H19/23, C07J41/0083, C07J43/003Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$60.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Cardiac myosin modulators for heart failure treatment and related small‑molecule synthesis
CPC C07D213/75, C07D413/12, C07D401/12Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$67.90m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C12Q1/6886, C12Q1/6883, G16B25/10Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
The most common specialisations among life sciences companies in San Francisco. Open a company to see what it sells, who runs it and how far it has come.
196 life sciences companies in San Francisco work in life sciences tech. Shown: the best-documented.
Life sciences techProvider of AI technology solutions for accelerating life sciences product development

Big data analyticsDeveloper of healthcare data platforms and artificial intelligence agent software
GenomicsProvider of a cloud-based bioinformatics platform for biotech research
Sales force automationProvider of AI-powered solutions for healthcare provider engagement in life sciences
Healthcare itDeveloper of an AI-powered platform for care coordination and disease detection
Healthcare itCompany provides healthcare analytics and value-based payments platform services
Life sciences techOnline platform for clinical trail data analytics and management software for researchers
Artificial intelligenceDeveloper of machine learning platform for drug discovery and development
Grc softwareProvider of cloud-based quality management software for the life science industry
Life sciences techProvider of cloud-based software for clinical trials
Life sciences techDeveloper of a bioinformatics platform for drug development and chemoproteomics
Life sciences techProvider of AI-based software for manufacturing operations

Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$557.35m across 8 disclosed equity rounds
Darker bars = larger roundsFocus: Integrating and analyzing de‑identified healthcare data across clouds for clinical decision support
CPC G16H10/60, G06F21/6254, G06F8/36Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$411.90m across 8 disclosed equity rounds
Darker bars = larger roundsFocus: Cloud-based bioprocess workflow and molecular design data management platform.
CPC G05B19/41865, G16C20/40, G06F21/6227Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$90.70m across 7 disclosed equity rounds
Darker bars = larger roundsFocus: AI-driven omnichannel marketing and sales optimization platforms using contextual decision models
CPC G06Q10/063116, G06Q30/0201, G06Q30/0202Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$251.99m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: AI-powered clinical triage for stroke, aneurysm, and cardiac signal analysis
CPC G06T7/0012, G16H30/40, G06Q10/06311Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$410.97m across 8 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$287.80m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$643.21m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: AI-driven biomedical data analysis and disease modeling for drug discovery and diagnostics
CPC G06V20/69, G06T7/0012, G16B40/20Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$63.91m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$32.03m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$235.50m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: KRAS G12C mutant inhibition using pyrido‑pyrimidine compounds for cancer therapy
CPC C07D519/00, A61P35/00, C07D487/04Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$44.65m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
118 life sciences companies in San Francisco work in genomics. Shown: the best-documented.
GenomicsDeveloper of a platform for detection of cancer

GenomicsVirtual eating disorder treatment and therapy, accessible and personalized care

GenomicsProvider of home-based genetic test for individuals
Life sciences platforms and toolsDeveloper of a semiconductor-based DNA synthesis platform
GenomicsDeveloper of genomics-based diagnostics for cancer
GenomicsDeveloper of instruments for life sciences industries
GenomicsProvider of a cloud-based bioinformatics platform for biotech research
GenomicsInnovating cancer detection for early, curable treatment through advanced technology
Healthcare booking platformsProvider of a genomic database for clinical research
Artificial intelligenceDeveloper of machine learning platform for drug discovery and development
GenomicsDeveloper of viral gene therapy
OncologyDeveloper of cell-based therapies for cancer treatment
US$138.97m across 4 disclosed equity rounds
Darker bars = larger rounds
Focus: Patents concentrated in chemistry & materials
CPC C12Q1/6886, C12N15/1093, G06Q30/0277Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.

Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$189.56m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in computing, sensing & instrumentation
CPC G16B20/20, C12Q1/6827, C12Q1/6869Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$320.76m across 9 disclosed equity rounds
Darker bars = larger roundsFocus: Synthetic DNA manufacturing, custom nucleic acid libraries, and related hybridization/enzymatic technologies.
CPC B01J19/0046, C07K16/2869, C12N15/1093Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$67.90m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C12Q1/6886, C12Q1/6883, G16B25/10Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$40.53m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in transport & manufacturing processes
CPC B01L3/502738, B01L3/502707, C12Q1/686Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$411.90m across 8 disclosed equity rounds
Darker bars = larger roundsFocus: Cloud-based bioprocess workflow and molecular design data management platform.
CPC G05B19/41865, G16C20/40, G06F21/6227Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Cancer diagnostic assays analyzing nucleic acid fragments for tumor detection
CPC C12Q1/6806, C12Q1/6886Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$435.00m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Genomic sequencing data management and cardiac genomics diagnostics analytics
CPC C12N15/8273, B21C37/121, G16B20/20Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$643.21m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: AI-driven biomedical data analysis and disease modeling for drug discovery and diagnostics
CPC G06V20/69, G06T7/0012, G16B40/20Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$239.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$158.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
117 life sciences companies in San Francisco work in oncology. Shown: the best-documented.
GenomicsDeveloper of a platform for detection of cancer

OncologyDeveloper of targeted antibody and T-cell therapeutics for treating multiple diseases
GenomicsDeveloper of genomics-based diagnostics for cancer
OncologyTreatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology.
Founders
Details not available
GenomicsInnovating cancer detection for early, curable treatment through advanced technology
ImmunotherapyDeveloper of chimeric antigen receptor cell therapy to treat cancer
Founders
Details not available
ImmunotherapyDeveloper of CAR- T therapy for cancer treatment
ImmunotherapyDevelope of synthetic neo-antigen targeting TILs through T cell isolation platform
Founders
Details not available
OncologyDeveloper of immune cell therapies for cancer treatment
ImmunotherapyDeveloper of cell therapies for the treatment of cancer
ImmunotherapyDeveloper of oncology-focused precision medicine using molecular diagnostics
Founders
Details not available
OncologyDeveloper of cell-based therapies for cancer treatment
US$138.97m across 4 disclosed equity rounds
Darker bars = larger rounds
Focus: Patents concentrated in chemistry & materials
CPC C12Q1/6886, C12N15/1093, G06Q30/0277Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$52.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$67.90m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in chemistry & materials
CPC C12Q1/6886, C12Q1/6883, G16B25/10Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$213.52m across 6 disclosed equity rounds
Darker bars = larger roundsFocus: Therapeutics targeting HIF prolyl hydroxylase inhibition and immuno‑modulatory antibodies (galectin‑9, CCR8).
CPC C07D217/26, A61K31/472, C07K16/22Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Cancer diagnostic assays analyzing nucleic acid fragments for tumor detection
CPC C12Q1/6806, C12Q1/6886Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$531.77m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Engineering allogeneic CAR‑T cells with immune‑evasion, switch receptors, and dosing technologies
CPC C12N5/0636, C07K14/715, A61K35/17Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Engineering and manufacturing of enhanced CAR‑T cells and cytokine gene therapies
CPC C12N5/0636, C07K14/7051, C07K14/71Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$200.50m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$631.16m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$157.36m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Targeted small‑molecule cancer therapies focusing on PKC, MAT2A, and splicing inhibition
CPC C07D417/14, A61K31/497, A61P35/00Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$158.00m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
100 life sciences companies in San Francisco work in life sciences platforms and tools. Shown: the best-documented.
Life sciences platforms and toolsDeveloper of a semiconductor-based DNA synthesis platform
Life sciences platforms and toolsManufacturer of flow cytometry systems for research applications
GenomicsDeveloper of instruments for life sciences industries
Life sciences platforms and toolsDeveloper of cell processing platforms for research and industries
Life sciences platforms and toolsManufacturer of a medical device for cell-based therapy
GenomicsProvider of single cell multiomics platform for genotypic and phenotypic analysis
GenomicsDeveloper of single-cell imaging and profiling platform based on magnetic levitation technology
GenomicsProvider of diagnostic solutions for systemic infections
Life sciences platforms and toolsProvider of animal microbiome based diagnostics services for pet care
Life sciences platforms and toolsProvider of biomanufacturing hardware and software tools for research purposes
Life sciences platforms and toolsDeveloper of genetically engineered strains of microorganisms
Life sciences platforms and toolsProvider of photomolecular biology platform to control cellular functions
US$320.76m across 9 disclosed equity rounds
Darker bars = larger roundsFocus: Synthetic DNA manufacturing, custom nucleic acid libraries, and related hybridization/enzymatic technologies.
CPC B01J19/0046, C07K16/2869, C12N15/1093Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$132.00m across 2 disclosed equity rounds
Darker bars = larger roundsFocus: Advanced fluidics, imaging, and calibration technologies for high‑throughput flow cytometry
CPC G01N15/1404, G01N15/1436, G01N15/1434Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$40.53m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in transport & manufacturing processes
CPC B01L3/502738, B01L3/502707, C12Q1/686Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$17.25m across 2 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$612.00m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Patents concentrated in transport & manufacturing processes
CPC B01L3/502715, C12M41/48, C12M35/02Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$110.00m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$73.77m across 4 disclosed equity rounds
Darker bars = larger roundsFocus: Magnetic/levitation particle separation technologies for biotech and material processing
CPC C12M47/04, B01L3/502761, B01L3/502753Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$191.47m across 3 disclosed equity rounds
Darker bars = larger roundsFocus: RNA-based rapid molecular diagnostic platforms for infectious and cardiac disease detection
CPC C12Q1/6883, G16B40/00, G16H50/20Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$25.88m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$107.22m across 4 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
US$7.67m across 3 disclosed equity rounds
Darker bars = larger roundsEach tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
Focus: Optogenetic platforms for scalable stem cell culture and directed cell differentiation
CPC C12N15/63, C12N5/0662, C12N5/0653Each tile appears only where data is on record. Founder photos and LinkedIn links appear where a profile matches exactly.
258 more company lists you can search, plus the Radar directory pages for each place.
No list matches. Try a shorter word.
We will reply with coverage, fields and pricing for your use case.
Filed revenue, profit and growth for every company on this page are available with a Radar account. Log in and you will come straight back here with all figures open.